Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7

Stem Cells and Development

Volumn 25, Issue 10, 2016, Pages 774-787

  Halpert, Matthew M ^a   Konduri, Vanaja ^a   Liang, Dan ^a   Chen, Yunyu ^a   Wing, James B ^b   Paust, Silke ^a   Levitt, Jonathan M ^a   Decker, William K ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b OSAKA UNIVERSITY   (Japan)

^c CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BYSTANDER SURFACE B7; CELL MEMBRANE PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; UNCLASSIFIED DRUG; B7 ANTIGEN; CTLA4 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ARTICLE; BYSTANDER EFFECT; CD8+ T LYMPHOCYTE; CELL PLASTICITY; CELL STRUCTURE; CELLULAR IMMUNITY; CONTROLLED STUDY; DOWN REGULATION; HEMATOPOIETIC CELL; IMMUNOREGULATION; IN VIVO STUDY; MELANOMA B16; MEMBRANE MICROPARTICLE; MOUSE; MYELOID DENDRITIC CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE SILENCING; HUMAN; INTRACELLULAR SPACE; METABOLISM; MONOCYTE;

ANIMALS; B7 ANTIGENS; BYSTANDER EFFECT; CTLA-4 ANTIGEN; DENDRITIC CELLS; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTRACELLULAR SPACE; MICE, INBRED C57BL; MONOCYTES; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84969216921     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2016.0009     Document Type: Article

References (50)

1. Krummel MF and JP Allison. (1995). CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459-465.
2. Waterhouse P, JM Penninger, E Timms, A Wakeham, A Shahinian, KP Lee, CB Thompson, H Griesser and TW Mak. (1995). Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-988.
3. Tivol EA, F Borriello, AN Schweitzer, WP Lynch, JA Bluestone and AH Sharpe. (1995). Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547.
4. Schubert D, C Bode, R Kenefeck, TZ Hou, JB Wing, A Kennedy, A Bulashevska, BS Petersen, AA Schaffer, et al. (2014). Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med 20: 1410-1416.
5. Kuehn HS, W Ouyang, B Lo, EK Deenick, JE Niemela, DT Avery, JN Schickel, DQ Tran, J Stoddar, et al. (2014). Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345:1623-1627.
6. Hodi FS, SJ O'Day, DF McDermott, RW Weber, JA Sosman, JB Haanen, R Gonzalez, C Robert, D Schadendorf, et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723.
7. Wing K, T Yamaguchi and S Sakaguchi. (2011). Cellautonomous and-non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol 32:428-433.
8. Qureshi Q, Y Zheng, K Nakamura, K Attridge, C Manzotti, EM Schmidt, J Baker, LE Jeffrey, S Kaur, et al. (2011). Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332: 600-603.
9. Dejean AS, DR Beisner, IL Ch'en, YM Kerdiles, A Babour, KC Arden, DH Castrillon, RA DePinho and SM Hedrick. (2009). Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat Immunol 10:504-513.
10. Grohmann U, C Orabona, F Fallarino, C Vacca, F Calcinaro, A Falorni, P Candeloro, ML Belladonna, R Bianchi, MC Fioretti and P Puccetti. (2002). CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 3:1097-1101.
11. Kowalczyk A, CA D'Souza and L Zhang. (2014). Cellextrinsic CTLA-4 mediated regulation of dendritic cell maturation depends on STAT3. Eur J Immunol 44:1143-1155.
12. Gardner D, LE Jeffrey and DM Sansom. (2014). Understanding the CD28/CTLA-4 (CD152) pathway and its implications for costimulatory blockade. Am J Transplant 14:1985-1991.
13. Wing K, Y Onishi, P Prieto-Martin, T Yamaguchi, M Miyara, Z Fehervari, T Nomura and S Sakaguchi. (2008). CTLA-4 control over Foxp3+ regulatory T cell function. Science 322:271-275.
14. Esposito L, KMD Hunter, J Clark, DB Rainbow, H Stevens, J Denesha, S Duley, S Dawson, G Coleman, et al. (2014). Investigation of soluble and transmembrane CTLA-4 isoforms in serum and microvesicles. J Immunol 193:889-900.
15. Daroszewski J, E Pawlak, L Karabon, I Frydecka, A Jonkisz, M Slowik, and M Bolanowski. (2009). Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. Eur J Endocrinol 161:787-793.
16. Purohit S, R Podolsky, C Collins, W Zheng, D Schatz, A Muir, D Hopkins, YH Huang and JX She. (2005). Lack of correlation between the levels of soluble cytotoxic Tlymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. J Autoimmune Dis 2:8.
17. Oaks MK and KM Hallett. (2000). Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J Immunol 164:5015-5018.
18. Read S, V Malmstrom and F Powrie. (2000). Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 192:295-302.
19. Linsley PS, JL Greene, P Tan, J Bradshaw, JA Ledbetter, C Anasetti and NK Damle. (1992). CTLA-4 coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 176:1595-1604.
20. Kuiper HM, M Brouwer, PS Linsley and van Lier RA. (1995). Activated T cells can induce high levels of CTLA-4 expression on B cells. J Immunol 155:177617-177683.
21. Sojanovic A, N Fiegler, M Brunner-Weinzierl and A Cerwenka. (2014). CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-g production in response to mature dendritic cells. J Immunol 192:4184-4191.
22. Masteller EL, E Chuang, AC Mullen, SL Reiner and CB Thompson. (2000). Structural analysis of CTLA-4 function in vivo. J Immunol 164:5319-5327.
23. Han Y, Z Chen, Y Yang, Z Jiang, Y Gu, Y Liu, C Lin, Z Pan, Y Yu, et al. (2014). Human CD14+CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology 59:567-579.
24. Wang XB, ZH Fan, D Anton, AV Vollenhoen, ZH Ni, XF Chen and AK Lefvert. (2011). CTLA4 is expressed on mature dendritic cells derived from human monocytes and influences their maturation and antigen presentation. BMC Immunol 12:21.
25. Laurent S, P Carrega, D Saverino, P Piccioli, M Camoriano, A Morabito, B Dozin, V Fontana, R Simone, et al. (2010). CTLA-4 is expressed by human monocytederived dendritic cells and regulates their functions. Hum Immunol 71:934-941.
26. Pistillo MP, PL Tazzari, GL Palmisano, I Pierri, A Bolognesi, F Ferlito, P Capanni, L Polito, M Ratta, et al. (2003). CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 101:202-209.
27. Decker WK, D Xing, S Li, SN Robinson, H Yang, D Steiner, KV Komanduri and EJ Shpall. (2009). Th-1 polarization is regulated by dendritic-cell comparison of MHC class I and II antigens. Blood 113:4213-4223.
28. Li G, S Abendiankenari, YJ Kim, TB Campbell, S Ito, B Graham-Evans, S Cooper and HE Broxmeyer. (2007). TGF-beta combined with M-CSF and IL-4 induces generation of immune inhibitory cord blood dendritic cells capable of enhancing cytokine-induced ex vivo expansion of myeloid progenitors. Blood 110:2872-2879.
29. Sobo-Vujanovic A, S Munich and NL Vujanovic. (2014). Dendritic-cell exosomes cross-present Toll-like receptorligands and activate bystander dendritic cells. Cell Immunol 289:119-127.
30. Wiley RD and S Gummuluru. (2006). Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection. Proc Natl Acad Sci U S A 103:738-743.
31. Azouz NP, N Zur, A Efergan, N Ohbayashi, M Fukuda, D Amihai, I Hammel, ME Rothenberg and R Sagi-Eisenberg. (2014). Rab5 is a novel regulator of mast cell secretory granules: impact on size, cargo, and exocytosis. J Immunol 192:4043-4053.
32. Ullrich O, S Reinsch, S Urbe, M Zerial and RG Parton. (1996). Rab11 regulates recycling through the pericentriolar recycling endosome. J Cell Biol 135:913-924.
33. Mandron M, MF Aries, RD Brehm, HS Tranter, KR Acharya, M Chaveron and C Davrinche. (2006). Human dendritic cells conditioned with Staphylococcus aureus enterotoxin B promote TH2 cell polarization. J Allergy Clin Immunol 117:1141-1147.
34. Brunet JF, F Denizot, MF Luciani, M Roux-Dosseto, M Suzan, MG Mattei and P Golstein. (1987). A new member of the immunoglobulin superfamily-CTLA-4. Nature 328: 267-270.
35. Friedline RH, DS Brown, H Nguyen, H Kornfeld, J Lee, Y Zhang, M Appleby, SD Der, J Kang and CA Chambers. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med 206:421-434.
36. Kalathil S, AA Lugade, A Miller, R Iyer and Y Thanavala. (2013). Higher frequencies of GARP+CTLA-4+Foxp3+ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res 73:2435-2444.
37. Verma C, JM Eremin, A Robbins, AJ Bennett, GP Cowley, MA El-Sheemy, JA Jibril and O Eremin. (2013). Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloidderived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med 11:16.
38. Montecalvo A, AT Larregina, WJ Shufesky, DB Stolz, ML Sullivan, JM Karlsson, CJ Baty, GA Gibson, G Erdos, et al. (2012). Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 119: 756-766.
39. Montecalvo A, WJ Shufesky, D Stolz, MG Sullivan, Z Wang, SJ Divito, GD Papworth, SC Watkins, PD Robbins, AT Larregina and AE Morelli. (2008). Exosomes as a shortrange mechanism to spread alloantigen between dendritic cells during T-cell allorecognition. J Immunol 180:3081-3090.
40. Valadi H, K Ekstrom, A Bossios, M Sjöstrand, JJ Lee and JO Lötvall. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654-659.
41. Montecalvo A, AT Larregina and AE Morelli. (2013). Methods of analysis of dendritic cell-derived exosomeshuttle microRNA and its horizontal propagation between dendritic cells. Methods Mol Biol 1024:19-40.
42. Wang X, J Wang, H Zheng, M Xie, EL Hopewell, RA Albrecht, S Nogusa, Garcia-A Sastre, S Balachandran and AA Beg. (2014). Differential requirement for the IKKb/NF-kB signaling module in regulating TLR-versus RLRinduced type 1 IFN expression in dendritic cells. J Immunol 193:2538-3545.
43. Ramos HJ and M Gale Jr. (2011). RIG-I like receptors and their signaling crosstalk in the regulation of antiviral immunity. Curr Opin Virol 1:167-176.
44. Decker WK and A Safdar. (2011). Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease. Cytokine Growth Factor Rev 22:177-187.
45. Delbridge LM and MX O'Riordan. (2007). Innate recognition of intracellular bacteria. Curr Opin Immunol 19:10-16.
46. Naidoo J, DB Page and JD Wolchok. (2014). Immune modulation for cancer therapy. Br J Cancer 111:2214-2219.
47. Blank CU. (2014). The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr Opin Oncol 26:204-214.
48. Simpson TR, F Li, W Montalvo-Ortiz, MA Sepulveda, K Bergerhoff, F Arce, C Roddie, JY Henry, H Yagita, et al. (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695-1710.
49. Le DT, E Lutz, JN Uram, EA Sugar, B Onners, S Solt, L Zheng, LA Diaz Jr., RC Donehower, EM Jaffee and DA Laheru. (2013). Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 36:382-389.
50. Kwon ED, AA Hurwitz, BA Foster, C Madias, AL Feldhaus, NM Greenberg, MB Burg and JP Allison. (1997). Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 94:8099-8103.